Monitan

Monitan - General Information

A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. [PubChem]

Pharmacology of Monitan

Monitan is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. In general, beta-blockers reduce the work the heart has to do and allow it to beat more regularly. Monitan has less antagonistic effects on peripheral vascular ß2-receptors at rest and after epinephrine stimulation than nonselective beta-antagonists. Low doses of acebutolol produce less evidence of bronchoconstriction than nonselective agents like propranolol but more than atenolol.

Monitan for patients

Monitan Interactions

Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents. Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia. Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops. Patients receiving beta-blockers should be warned of this potential hazard.

Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.

No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.

Monitan Contraindications

Acebutolol hydrochloride capsules are contraindicated in: 1) persistently severe bradycardia; 2) second- and third-degree heart block; 3) overt cardiac failure; and 4) cardiogenic shock.

Additional information about Monitan

Monitan Indication: For the management of hypertension and ventricular premature beats in adults.
Mechanism Of Action: Monitan is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Monitan blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels.
Drug Interactions: Acetohexamide Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
Chlorpropamide Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
Disopyramide Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
Gliclazide Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
Glipizide Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
Glibenclamide Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
Lidocaine Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
Repaglinide Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
Tolazamide Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
Tolbutamide Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
Clonidine Increased hypertension when clonidine stopped
Dihydroergotamine Ischemia with risk of gangrene
Ergotamine Ischemia with risk of gangrene
Methysergide Ischemia with risk of gangrene
Epinephrine Hypertension, then bradycardia
Ibuprofen Risk of inhibition of renal prostaglandins
Indomethacin Risk of inhibition of renal prostaglandins
Piroxicam Risk of inhibition of renal prostaglandins
Prazosin Risk of hypotension at the beginning of therapy
Verapamil Increased effect of both drugs
Isoproterenol Antagonism
Salmeterol Antagonism
Terbutaline Antagonism
Dihydroergotoxine Ischemia with risk of gangrene
Ergonovine Ischemia with risk of gangrene
Fenoterol Antagonism
Glisoxepide The beta-blocker decreases the symptoms of hypoglycemia
Orciprenaline Antagonism
Pirbuterol Antagonism
Fenoterol Antagonism
Insulin-aspart The beta-blocker decreases the symptoms of hypoglycemia
Insulin-detemir The beta-blocker decreases the symptoms of hypoglycemia
Insulin-glargine The beta-blocker decreases the symptoms of hypoglycemia
Insulin-glulisine The beta-blocker decreases the symptoms of hypoglycemia
Insulin-lispro The beta-blocker decreases the symptoms of hypoglycemia
Lidocaine The beta-blocker increases the effect and toxicity of lidocaine
Pirbuterol Antagonism
Orciprenaline Antagonsim
Food Interactions: Take without regard to meals; absorption rate and maximal concentration are slightly reduced but the extent of absorption is not affected.
Generic Name: Acebutolol
Synonyms: dl-Acebutolol; Acetobutolol; Acebutololo; Acebutolol HCL
Drug Category: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents
Drug Type: Small Molecule; Approved

Other Brand Names containing Acebutolol: Monitan; Neptal; Prent; Sectral;
Absorption: Well absorbed from the Gl tract with an absolute bioavailability of approximately 40% for the parent compound. In
Toxicity (Overdose): Symptoms of overdose include extreme bradycardia, advanced atrioventricular block, intraventricular conduction defects, hypotension, severe congestive heart failure, seizures, and in susceptible patients, bronchospasm, and hypoglycemia.
Protein Binding: 26%
Biotransformation: Subject to extensive first-pass hepatic biotransformation (primarily to diacetolol).
Half Life: The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.
Dosage Forms of Monitan: Tablet Oral
Chemical IUPAC Name: N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide
Chemical Formula: C18H28N2O4
Acebutolol on Wikipedia: https://en.wikipedia.org/wiki/Acebutolol
Organisms Affected: Humans and other mammals